3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
blinatumomab
4
fludarabine
3
Rituximab
3
Cyclophosphamide
3
ponatinib
2
ibrutinib
2
fludarabine phosphate
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
Bone Marrow Transplantation
2
venetoclax
1
tetulomab tetraxetan lu-177
1
pomalidomide
1
obinutuzumab
1
durvalumab
1
dacetuzumab
1
amonafide
1
acalabrutinib
1
Tinzaparin
1
Lutetium-177
1
Lutetium
1
Lenalidomide
1
Imatinib Mesylate
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Diseases
×
Tinzaparin
×
Other hematologic neoplasm
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled